My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 109

    1.

    Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents.

    Rosenstock J, Bergenstal R, Defronzo RA, Hirsch IB, Klonoff D, Boss AH, Kramer D, Petrucci R, Yu W, Levy B; 0008 Study Group.

    Diabetes Care. 2008 Nov;31(11):2177-82. Epub 2008 Aug 4.PMID: 18678610 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

    Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

    Clin Ther. 2008 Aug;30(8):1448-60. Erratum in: Clin Ther. 2008 Oct;30(10):1937. PMID: 18803987 [PubMed - indexed for MEDLINE]Related articles

    3.

    Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.

    Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.

    Clin Ther. 2007 Nov;29(11):2374-84.PMID: 18158078 [PubMed - indexed for MEDLINE]Related articles

    4.

    Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial.

    Rosenstock J, Zinman B, Murphy LJ, Clement SC, Moore P, Bowering CK, Hendler R, Lan SP, Cefalu WT.

    Ann Intern Med. 2005 Oct 18;143(8):549-58.PMID: 16230721 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.

    Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group.

    Ann Intern Med. 2005 Oct 18;143(8):559-69.PMID: 16230722 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.

    Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME.

    Clin Ther. 2007 Nov;29(11):2333-48.PMID: 18158075 [PubMed - indexed for MEDLINE]Related articles

    7.

    Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.

    Luis Bautista J, Bugos C, Dirnberger G, Atherton T.

    Clin Ther. 2003 Jan;25(1):194-209.PMID: 12637120 [PubMed - indexed for MEDLINE]Related articles

    8.

    Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

    Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles

    9.

    An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea.

    Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M.

    Diabetes Care. 2006 Jun;29(6):1282-7.PMID: 16732009 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus.

    Herz M, Sun B, Milicevic Z, Erickson P, Fövènyi J, Grzywa M, Pelikanova T.

    Clin Ther. 2002 Jan;24(1):73-86.PMID: 11833837 [PubMed - indexed for MEDLINE]Related articles

    11.

    Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

    Roberts VL, Stewart J, Issa M, Lake B, Melis R.

    Clin Ther. 2005 Oct;27(10):1535-47.PMID: 16330290 [PubMed - indexed for MEDLINE]Related articles

    12.

    Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.

    Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A.

    Diabetes Obes Metab. 2006 Nov;8(6):650-60.PMID: 17026489 [PubMed - indexed for MEDLINE]Related articles

    13.

    Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.

    Tîrgovişte CI, Străchinariu R, Farcaşiu E, Milicevic Z, Teodorescu G.

    Rom J Intern Med. 2003;41(2):153-62.PMID: 15526500 [PubMed - indexed for MEDLINE]Related articles

    14.

    A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.

    Hollander P, Cooper J, Bregnhøj J, Pedersen CB.

    Clin Ther. 2008 Nov;30(11):1976-87.PMID: 19108786 [PubMed - indexed for MEDLINE]Related articles

    15.

    Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes.

    Kelley DE, Bidot P, Freedman Z, Haag B, Podlecki D, Rendell M, Schimel D, Weiss S, Taylor T, Krol A, Magner J.

    Diabetes Care. 1998 Dec;21(12):2056-61.PMID: 9839094 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.

    Riddle M, Frias J, Zhang B, Maier H, Brown C, Lutz K, Kolterman O.

    Diabetes Care. 2007 Nov;30(11):2794-9. Epub 2007 Aug 13.PMID: 17698615 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.

    Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA.

    Clin Ther. 2005 Aug;27(8):1181-95.PMID: 16199244 [PubMed - indexed for MEDLINE]Related articles

    18.

    Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

    Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

    Diabetes Care. 2006 Mar;29(3):554-9.PMID: 16505505 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Low-dose rosiglitazone in patients with insulin-requiring type 2 diabetes.

    Hollander P, Yu D, Chou HS.

    Arch Intern Med. 2007 Jun 25;167(12):1284-90.PMID: 17592102 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control.

    Rosenstock J, Rood J, Cobitz A, Huang C, Garber A.

    Diabetes Obes Metab. 2006 Nov;8(6):643-9.PMID: 17026488 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity